NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Short Interest Update

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) was the recipient of a large drop in short interest in February. As of February 27th, there was short interest totaling 926,133 shares, a drop of 75.9% from the February 12th total of 3,839,273 shares. Based on an average trading volume of 665,099 shares, the short-interest ratio is presently 1.4 days. Approximately 6.4% of the shares of the stock are short sold. Approximately 6.4% of the shares of the stock are short sold. Based on an average trading volume of 665,099 shares, the short-interest ratio is presently 1.4 days.

Institutional Trading of NovaBay Pharmaceuticals

A number of hedge funds have recently made changes to their positions in NBY. Geode Capital Management LLC grew its position in NovaBay Pharmaceuticals by 2,331.7% in the fourth quarter. Geode Capital Management LLC now owns 1,257,705 shares of the biopharmaceutical company’s stock worth $7,098,000 after acquiring an additional 1,205,984 shares in the last quarter. State Street Corp lifted its stake in NovaBay Pharmaceuticals by 970.5% during the fourth quarter. State Street Corp now owns 313,703 shares of the biopharmaceutical company’s stock worth $1,769,000 after purchasing an additional 284,400 shares during the last quarter. Goldman Sachs Group Inc. purchased a new position in shares of NovaBay Pharmaceuticals in the 4th quarter worth about $588,000. Charles Schwab Investment Management Inc. purchased a new position in shares of NovaBay Pharmaceuticals in the 4th quarter worth about $526,000. Finally, Jane Street Group LLC bought a new position in shares of NovaBay Pharmaceuticals during the 4th quarter valued at about $395,000. 23.25% of the stock is owned by institutional investors.

NovaBay Pharmaceuticals Trading Down 1.8%

Shares of NBY traded down $0.02 during trading hours on Wednesday, reaching $1.24. 231,704 shares of the company’s stock traded hands, compared to its average volume of 472,389. NovaBay Pharmaceuticals has a 12 month low of $1.11 and a 12 month high of $99.75. The stock has a market cap of $32.06 million, a PE ratio of -0.12 and a beta of 0.25. The firm’s 50 day simple moving average is $20.05 and its 200-day simple moving average is $13.32.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, non-antibiotic anti-infective products designed to regulate the innate immune response. Leveraging its proprietary Aganocide® Technology, the company’s synthetic antimicrobial compounds target and neutralize pathogens without contributing to antibiotic resistance. NovaBay’s research and development efforts concentrate on ophthalmic, dermatological and wound care applications, aiming to address unmet needs in infection control and inflammation management.

The company’s primary commercial products include Avenova®, an eyelid and lash cleaning solution indicated for managing chronic blepharitis and meibomian gland dysfunction, and NeutroPhase®, a pure hypochlorous acid wound and skin cleanser used in acute and chronic wound irrigation.